DISTINCTIVE FEATURES OF PHENOTYPIC CHARACTERISTICS OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN THE POPULATION OF AZERBAIJAN

Authors:

Abstract:

The study included 120 patients with the bronchitic phenotype, 20 patients with the emphysematous phenotype of chronic obstructive pulmonary disease, and 20 apparently healthy persons, aged 30–65 years. Body mass index was calculated using the formula: BMI = weight, kg / height, m² (kg/m²). Obesity was registered at a body mass index of ≥30 kg/m². Blood pressure was measured by the Korotkoff method. Systolic and diastolic blood pressure were determined. The study of the concentration of major lipids in blood plasma was performed on an empty stomach after a 14-hour fast, using the Cobas 6000 analyzer by an enzymatic colorimetric method. The body mass index data indicated a predominance of obesity in individuals with the bronchitic phenotype of chronic obstructive pulmonary disease. Contrary to the commonly accepted view that hyperlipidemia is characteristic of the bronchitic phenotype of chronic obstructive pulmonary disease, this form of lipid metabolism disorder was also detected in the emphysematous phenotype of the disease. Thus, the results of the study established a clear tendency toward the development of cardiovascular comorbid pathology in the presence of both the bronchitic and emphysematous phenotypes of chronic obstructive pulmonary disease.

Keywords:

chronic obstructive pulmonary disease bronchitic phenotype emphysematous phenotype risk factors plasma lipids hyperlipidemia

References:

1. Ali A, Wu L, Elfeky S, Moazen EM, Elshormilisy AA, Eissa AM, et al. Metabolic syndrome in chronic obstructive pulmonary disease: paradoxical relationships between systemic inflammation, oxygenation, and lipid profiles with implications for one-year clinical outcomes. Egypt. J Bronchol. 2026; 20:134-147. https://doi.org/10.1186/s43168-026-00644-x
2. Bakeer M, Funk GC, Valipour A. Chronic obstructive pulmonary disease phenotypes: imprint on pharmacological and non-pharmacological therapy. Ann Transl Med 2020;8(21):1472. doi: 10.21037/atm-20-2219
3. Bao H, Jia G, Cong S, Sun W, Fan J, Wang N, et al. Phenotype and management of chronic obstructive pulmonary disease patients in general population in China: A nationally cross-sectional study. NPJ Prim. Care Respir. Med. 2021;31:32. doi: 10.1038/s41533-021-00243-x.
4. Brandsma C-A, Van den Berge M, Hackett T-L, Brusselle G, Timens W. Recent advances in chronic obstructive pulmonary disease pathogenesis: from disease mechanisms to precision medicine. Journal Of Pathology. 2020;250(5):624–35.
5. Brat K, Svoboda M, Zatloukal J, Plutinsky M, Volakova E, Popelkova P, et al. The Relation Between Clinical Phenotypes, GOLD Groups/Stages and Mortality in COPD Patients - A Prospective Multicenter Study. Int J Chron Obstruct Pulmon Dis. 2021 Apr 28;16:1171-1182. doi: 10.2147/COPD.S297087.
6. Cobb K, Kenyon J, Lu J, Krieger B, Perelas A, Nana-Sinkam P, et al. COPD is associated with increased cardiovascular disease risk independent of phenotype. Respirology. 2024 Dec;29(12):1047-1057. doi: 10.1111/resp.14799.
7. Ilievska DB, Mickovski I, Milosheska R, Trajkova V, Stoshevska TD. Comparative study of lipid profiles in patients at various stages of chronic obstructive pulmonary disease. Medical Research Journal. 2026;11, e04426056 DOI:10.5603/mrj.113273
8. Jha RK, Mahajan Sh, Mehta D, Ambad RS, Koundal P. Lipid profile in patients with COPD: cross- sectional study. International Journal of Medical and Biomedical Studies. 2020; 4 (1): 121-126. DOI: https://doi.org/10.32553/ijmbs.v4i1.879.
9. Koo HK, Chung SJ, Park D, Kim HC, Seo H, Kim HJ, et al. Comparing Heterogenous Phenotypes of Chronic Obstructive Pulmonary Disease: Network Analysis and Penalized Generalized Linear Model. Int J Chron Obstruct Pulmon Dis. 2025;20:1267-1277. https://doi.org/10.2147/COPD.S496199.
10. Lei YF, Lin HC, Lin HL, Uang YS, Cheng HW, Wang LH. Association Between Use of Antihyperlipidemic Agents and Chronic Obstructive Pulmonary Disease in Patients with Hyperlipidemia: A Population-Based Retrospective Cohort Study. Int J Chron Obstruct Pulmon Dis. 2020 Oct 20;15:2573-2581. doi: 10.2147/COPD.S267017.
11. Li M, Xu B, Yu H, Wan Y, Zhu Z, Luo P, et al. Associations between serum lipid profiles and the incidence of chronic obstructive pulmonary disease in the UK Biobank. Journal of Health, Population and Nutrition, 2025; 44(1), 281. https://doi.org/10.1186/s41043-025-01026-716.
12. Liang Q, Wang Y, Li Z. Lipid metabolism reprogramming in chronic obstructive pulmonary disease. Mol Med. 2025 31, 129. https://doi.org/10.1186/s10020-025-01191-9.
13. Ozlu T, Sengoren DO, Turkis FC, Degirmenci C, Ilgazlı A, Gülmez I, et al. Clinical and Functional Heterogeneity of COPD Phenotypes: A Multicenter Study from Turkey (DIPTUR Study). Medicina. 2026; 62(2):402. https://doi.org/10.3390/medicina62020402
14. Tudoric N, Koblizek V, Miravitlles M, Valipour A, Milenkovic B, Barczyk A, et al. GOLD 2017 on the way to a phenotypic approach? Analysis from the Phenotypes of COPD in Central and Eastern Europe (POPE) Cohort. Eur Respir J. 2017 Apr 26;49(4):1602518. doi: 10.1183/13993003.02518-2016.
15. Vicol C, Buculei I, Melinte OE, Dobrin ME, Stavarache EI, Gavrilescu CM, et al. The Lipid Profile and Biochemical Parameters of COPD Patients in Relation to Smoking Status. Biomedicines. 2022 Nov 15;10(11):2936. doi: 10.3390/biomedicines10112936.
16. Zeng Y, Wang X, Lin X. Associations between serum lipid profiles and the incidence of chronic obstructive pulmonary disease in heavily smoking cohorts. Respiratory Research. 2025; 26(1):102–114.
17. Zhao S, Zheng L, Zhu M, Shui Y, Bao X, Zhao J. Intensive Intervention Improves Outcomes for Chronic Obstructive Pulmonary Disease Patients: A Medical Consortium-Based Management. Can Respir J. 2022 Jun 27;2022:6748330. doi: 10.1155/2022/6748330.

Publication:

«World of Medicine and Biology» Vol. 22 No. 97 (2026), pp. 115-119
UDC 616.24-036.12-06

DOI:

https://doi.org/10.26724/2079-8334-2026-3-97-115-119